9.295 -0.085 (-0.91%) | 02-06 10:01 | |||||||||||||
|
|
Short term | ![]() ![]() ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 11.8 | 1-year : | 13.7 |
Resists | First : | 10.1 | Second : | 11.72 |
Pivot price | 9.41 ![]() |
|||
Supports | First : | 7.47 | Second : | 6.21 |
MAs | MA(5) : | 9.27 ![]() |
MA(20) : | 9.08 ![]() |
MA(100) : | 8.23 ![]() |
MA(250) : | 0 | |
MACD | MACD : | 0.2 ![]() |
Signal : | 0.2 ![]() |
%K %D | K(14,3) : | 37.7 ![]() |
D(3) : | 39.3 ![]() |
RSI | RSI(14): 53.5 ![]() |
|||
52-week | High : | 11.72 | Low : | 5.51 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ACTU ] has closed above bottom band by 45.4%. Bollinger Bands are 22.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 9.52 - 9.56 | 9.56 - 9.59 |
Low: | 8.75 - 8.79 | 8.79 - 8.83 |
Close: | 9.36 - 9.44 | 9.44 - 9.5 |
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.
Thu, 06 Feb 2025
Actuate Therapeutics to Participate in Upcoming Investor Conferences in February - GlobeNewswire
Tue, 28 Jan 2025
Why IMAC Holdings Shares Are Trading Higher By Over 108%; Here Are 20 Stocks Moving Premarket - Benzinga
Fri, 24 Jan 2025
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Wed, 08 Jan 2025
Actuate Therapeutics (NASDAQ:ACTU) Shares Down 2.1% - What's Next? - MarketBeat
Tue, 17 Dec 2024
Actuate Therapeutics Announces Positive Interim Phase 2 - GlobeNewswire
Tue, 26 Nov 2024
Actuate Therapeutics to be Added to Russell 2000® Index - GlobeNewswire
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 20 (M) |
Shares Float | 7 (M) |
Held by Insiders | 18.6 (%) |
Held by Institutions | 53 (%) |
Shares Short | 20 (K) |
Shares Short P.Month | 13 (K) |
EPS | -1.47 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | -58.92 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | 0 % |
Return on Equity (ttm) | 0 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -19 (M) |
Levered Free Cash Flow | 0 (M) |
PE Ratio | -6.37 |
PEG Ratio | 0 |
Price to Book value | -0.16 |
Price to Sales | 0 |
Price to Cash Flow | -9.52 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |